{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:31:08Z","timestamp":1790317868036,"version":"4.1.0"},"reference-count":70,"publisher":"Hindawi Limited","issue":"6","license":[{"start":{"date-parts":[[2014,9,9]],"date-time":"2014-09-09T00:00:00Z","timestamp":1410220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2014,9,9]],"date-time":"2014-09-09T00:00:00Z","timestamp":1410220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1111\/jcpt.12200","type":"journal-article","created":{"date-parts":[[2014,9,9]],"date-time":"2014-09-09T11:45:59Z","timestamp":1410263159000},"page":"584-608","source":"Crossref","is-referenced-by-count":73,"title":["Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review"],"prefix":"10.1155","volume":"39","author":[{"given":"A. K.","family":"Polso","sequence":"first","affiliation":[{"name":"Department of Pharmacy; University of Michigan Hospitals and Health Centers; Ann Arbor MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Lassiter","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; University of Michigan Hospitals and Health Centers; Ann Arbor MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Nagel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; University of Michigan Hospitals and Health Centers; Ann Arbor MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2014,9,9]]},"reference":[{"key":"10.1111\/jcpt.12200-BIB0001|jcpt12200-cit-0001","first-page":"1","article-title":"Prevalence of obesity in the United States, 2009-2010","volume":"82","author":"Ogden","year":"2012","journal-title":"NCHS Data Brief"},{"key":"10.1111\/jcpt.12200-BIB0002|jcpt12200-cit-0002","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/BF00542215","article-title":"Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients","volume":"24","author":"Bauer","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12200-BIB0003|jcpt12200-cit-0003","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1378\/chest.122.4.1256","article-title":"The relation of body mass index to asthma, chronic bronchitis, and emphysema","volume":"122","author":"Guerra","year":"2002","journal-title":"Chest"},{"key":"10.1111\/jcpt.12200-BIB0004|jcpt12200-cit-0004","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.pupt.2012.04.006","article-title":"Obesity and respiratory infections: does excess adiposity weigh down host defense?","volume":"26","author":"Mancuso","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1111\/jcpt.12200-BIB0005|jcpt12200-cit-0005","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1473-3099(06)70523-0","article-title":"Obesity and infection","volume":"6","author":"Falagas","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/jcpt.12200-BIB0006|jcpt12200-cit-0006","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/clpt.2011.104","article-title":"Implications of obesity for drug therapy: limitations and challenges","volume":"90","author":"Jain","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12200-BIB0007|jcpt12200-cit-0007","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","volume":"49","author":"Hanley","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jcpt.12200-BIB0008|jcpt12200-cit-0008","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1365-2125.1983.tb02258.x","article-title":"Serum alpha 1-acid glycoprotein and the binding of drugs in obesity","volume":"16","author":"Benedek","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12200-BIB0009|jcpt12200-cit-0009","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","article-title":"Impact of obesity on drug metabolism and elimination in adults and children","volume":"51","author":"Brill","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jcpt.12200-BIB0010|jcpt12200-cit-0010","doi-asserted-by":"crossref","first-page":"872894","DOI":"10.1155\/2012\/872894","article-title":"Creatinine-based estimations of kidney function are unreliable in obese kidney donors","volume":"2012","author":"Aggarwal","year":"2012","journal-title":"J Transplant"},{"key":"10.1111\/jcpt.12200-BIB0011|jcpt12200-cit-0011","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1128\/AAC.01083-12","article-title":"Case-control study of drug monitoring of beta-lactams in obese critically ill patients","volume":"57","author":"Hites","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12200-BIB0012|jcpt12200-cit-0012","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/infdis\/138.4.499","article-title":"A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects","volume":"138","author":"Schwartz","year":"1978","journal-title":"J Infect Dis"},{"key":"10.1111\/jcpt.12200-BIB0013|jcpt12200-cit-0013","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cpt1979264508","article-title":"Tobramycin pharmacokinetics in morbidly obese patients","volume":"26","author":"Blouin","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12200-BIB0014|jcpt12200-cit-0014","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1128\/AAC.00174-11","article-title":"Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients","volume":"55","author":"Pai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12200-BIB0015|jcpt12200-cit-0015","first-page":"549","article-title":"Administration o gentamicin to obese patients","volume":"18","author":"Korsager","year":"1980","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1111\/jcpt.12200-BIB0016|jcpt12200-cit-0016","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/j.1552-4604.1981.tb01769.x","article-title":"Effect of obesity on gentamicin pharmacokinetics","volume":"21","author":"Sketris","year":"1981","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/jcpt.12200-BIB0017|jcpt12200-cit-0017","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2165\/00003088-200443150-00007","article-title":"A standard weight descriptor for dose adjustment in the obese patient","volume":"43","author":"Duffull","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jcpt.12200-BIB0018|jcpt12200-cit-0018","first-page":"519","article-title":"Amikacin pharmacokinetics in morbidly obese patients","volume":"37","author":"Bauer","year":"1980","journal-title":"Am J Hosp Pharm"},{"key":"10.1111\/jcpt.12200-BIB0019|jcpt12200-cit-0019","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0002-9378(85)80186-1","article-title":"Aminoglycoside dosing in obese puerperal women","volume":"152","author":"Gibbs","year":"1985","journal-title":"Am J Obstet Gynecol"},{"key":"10.1111\/jcpt.12200-BIB0020|jcpt12200-cit-0020","first-page":"70","article-title":"Amikacin pharmacokinetics in morbidly obese patients undergoing gastric-bypass surgery","volume":"4","author":"Blouin","year":"1985","journal-title":"Clin Pharm"},{"key":"10.1111\/jcpt.12200-BIB0021|jcpt12200-cit-0021","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1008708119954","article-title":"Relationship between pharmacokinetic parameters of gentamicin and patient characteristics and\/or clinical data in patients with solid organ tumours","volume":"21","author":"Ortega","year":"1999","journal-title":"Pharm World Sci"},{"key":"10.1111\/jcpt.12200-BIB0022|jcpt12200-cit-0022","volume-title":"Tobramycin","year":"2008"},{"key":"10.1111\/jcpt.12200-BIB0023|jcpt12200-cit-0023","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/cid\/cir611","article-title":"Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system","volume":"53","author":"Pogue","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1111\/jcpt.12200-BIB0024|jcpt12200-cit-0024","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1128\/AAC.01707-09","article-title":"Colistin dosing and nephrotoxicity in a large community teaching hospital","volume":"54","author":"Deryke","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12200-BIB0025|jcpt12200-cit-0025","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1128\/AAC.00028-12","article-title":"Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients","volume":"56","author":"Gauthier","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12200-BIB0026|jcpt12200-cit-0026","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12200-BIB0027|jcpt12200-cit-0027","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/archinte.1966.00290160026006","article-title":"Acute renal failure associated with sodium colistimethate treatment","volume":"118","author":"Elwood","year":"1966","journal-title":"Arch Intern Med"},{"key":"10.1111\/jcpt.12200-BIB0028|jcpt12200-cit-0028","volume-title":"Cubicin (daptomycin)","year":"2013"},{"key":"10.1111\/jcpt.12200-BIB0029|jcpt12200-cit-0029","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1128\/AAC.00059-07","article-title":"Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin","volume":"51","author":"Pai","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12200-BIB0030|jcpt12200-cit-0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/0091270004269562","article-title":"The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects","volume":"45","author":"Dvorchik","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/jcpt.12200-BIB0031|jcpt12200-cit-0031","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/AAC.00943-08","article-title":"Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever","volume":"53","author":"Bubalo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12200-BIB0032|jcpt12200-cit-0032","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1345\/aph.1P745","article-title":"TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient","volume":"45","author":"Pea","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1111\/jcpt.12200-BIB0033|jcpt12200-cit-0033","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1111\/jcpt.12200-BIB0034|jcpt12200-cit-0034","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/phar.1298","article-title":"Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern united states","volume":"33","author":"Bookstaver","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12200-BIB0035|jcpt12200-cit-0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1128\/AAC.01018-13","article-title":"Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes","volume":"58","author":"Ng","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12200-BIB0036|jcpt12200-cit-0036","volume-title":"Synercid (quinupristin and dalfopristin)","year":"2012"},{"key":"10.1111\/jcpt.12200-BIB0037|jcpt12200-cit-0037","volume-title":"20th International Congress of Chemotherapy, Sydney, Australia","author":"Lefebvre","year":"1997"},{"key":"10.1111\/jcpt.12200-BIB0038|jcpt12200-cit-0038","volume-title":"Bactrim (sulfamethoxazole and trimethoprim DS)","year":"2013"},{"key":"10.1111\/jcpt.12200-BIB0039|jcpt12200-cit-0039","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/bdd.2510020405","article-title":"Surgically affected sulfisoxazole pharmacokinetics in the morbidly obese","volume":"2","author":"Garrett","year":"1981","journal-title":"Biopharm Drug Dispos"},{"key":"10.1111\/jcpt.12200-BIB0040|jcpt12200-cit-0040","volume-title":"Vancomycin hydrochloride [package insert]","author":"Baxter Healthcare Corporation","year":"2011"},{"key":"10.1111\/jcpt.12200-BIB0041|jcpt12200-cit-0041","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s002280050524","article-title":"Vancomycin dosing in morbidly obese patients","volume":"54","author":"Bauer","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12200-BIB0042|jcpt12200-cit-0042","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1128\/AAC.37.3.436","article-title":"Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a bayesian forecasting technique","volume":"37","author":"Vance-Bryan","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12200-BIB0043|jcpt12200-cit-0043","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00007691-199806000-00005","article-title":"Therapeutic drug monitoring of vancomycin in a morbidly obese patient","volume":"20","author":"Penzak","year":"1998","journal-title":"Ther Drug Monit"},{"key":"10.1111\/jcpt.12200-BIB0044|jcpt12200-cit-0044","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1128\/AAC.21.4.575","article-title":"Vancomycin pharmacokinetics in normal and morbidly obese subjects","volume":"21","author":"Blouin","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12200-BIB0045|jcpt12200-cit-0045","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00007691-199410000-00013","article-title":"Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight","volume":"16","author":"Ducharme","year":"1994","journal-title":"Ther Drug Monit"},{"key":"10.1111\/jcpt.12200-BIB0046|jcpt12200-cit-0046","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2146\/ajhp100410","article-title":"Determining vancomycin clearance in an overweight and obese population","volume":"68","author":"Leong","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"10.1111\/jcpt.12200-BIB0047|jcpt12200-cit-0047","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2146\/ajhp110324","article-title":"Performance of a vancomycin dosage regimen developed for obese patients","volume":"69","author":"Reynolds","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1111\/jcpt.12200-BIB0048|jcpt12200-cit-0048","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/phar.1321","article-title":"Vancomycin trough concentrations in overweight or obese pediatric patients","volume":"33","author":"Heble","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12200-BIB0049|jcpt12200-cit-0049","volume-title":"AmBisome (amphotericin B)","year":"2012"},{"key":"10.1111\/jcpt.12200-BIB0050|jcpt12200-cit-0050","first-page":"465","article-title":"Disposition and toxicity of amphotericin-B in the hyperlipidemic zucker rat model","volume":"14","author":"Vadiei","year":"1990","journal-title":"Int J Obes"},{"key":"10.1111\/jcpt.12200-BIB0051|jcpt12200-cit-0051","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1128\/AAC.44.2.408-410.2000","article-title":"Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits","volume":"44","author":"Groll","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12200-BIB0052|jcpt12200-cit-0052","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/AAC.28.1.144","article-title":"Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits","volume":"28","author":"Koldin","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12200-BIB0053|jcpt12200-cit-0053","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1128\/AAC.45.4.1184-1191.2001","article-title":"Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities","volume":"45","author":"Ramaswamy","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12200-BIB0054|jcpt12200-cit-0054","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/j.1875-9114.1995.tb04361.x","article-title":"Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection","volume":"15","author":"Gillum","year":"1995","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12200-BIB0055|jcpt12200-cit-0055","volume-title":"Vfend","author":"Pfizer Inc.","year":"2011"},{"key":"10.1111\/jcpt.12200-BIB0056|jcpt12200-cit-0056","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/AAC.01765-10","article-title":"Steady-state plasma pharmacokinetics of oral voriconazole in obese adults","volume":"55","author":"Pai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12200-BIB0057|jcpt12200-cit-0057","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1093\/jac\/dks312","article-title":"Evaluation of the effect of obesity on voriconazole serum concentrations","volume":"67","author":"Koselke","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12200-BIB0058|jcpt12200-cit-0058","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/phar.1156","article-title":"Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review","volume":"33","author":"Davies-Vorbrodt","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12200-BIB0059|jcpt12200-cit-0059","doi-asserted-by":"crossref","first-page":"e877","DOI":"10.1111\/j.1439-0507.2011.02016.x","article-title":"Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction","volume":"54","author":"Moriyama","year":"2011","journal-title":"Mycoses"},{"key":"10.1111\/jcpt.12200-BIB0060|jcpt12200-cit-0060","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1002\/phar.1192","article-title":"Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype","volume":"33","author":"Moriyama","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12200-BIB0061|jcpt12200-cit-0061","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/cid\/cir511","article-title":"Dosing voriconazole in an obese patient","volume":"53","author":"Dickmeyer","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1A","key":"10.1111\/jcpt.12200-BIB0062|jcpt12200-cit-0062","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0002-9343(82)90088-2","article-title":"Overview of acyclovir pharmacokinetic disposition in adults and children","volume":"73","author":"Blum","year":"1982","journal-title":"Am J Med"},{"key":"10.1111\/jcpt.12200-BIB0063|jcpt12200-cit-0063","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00003088-198308030-00001","article-title":"CLinical pharmacokinetics of acyclovir","volume":"8","author":"Laskin","year":"1983","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jcpt.12200-BIB0064|jcpt12200-cit-0064","volume-title":"Programs and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Davis","year":"1991"},{"key":"10.1111\/jcpt.12200-BIB0065|jcpt12200-cit-0065","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2146\/ajhp080307","article-title":"Acyclovir-induced renal failure in an obese patient","volume":"66","author":"Hernandez","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1111\/jcpt.12200-BIB0066|jcpt12200-cit-0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bcr-2012-006264","article-title":"Acyclovir-induced acute renal failure and the importance of an expanding waist line","volume":"2012","author":"Seedat","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1111\/jcpt.12200-BIB0067|jcpt12200-cit-0067","volume-title":"Zovirax (acyclovir sodium)","year":"2003"},{"key":"10.1111\/jcpt.12200-BIB0068|jcpt12200-cit-0068","volume-title":"Vistide (cidofovir injection)","year":"2000"},{"key":"10.1111\/jcpt.12200-BIB0069|jcpt12200-cit-0069","volume-title":"Foscavir (foscarnet sodium)","year":"2012"},{"key":"10.1111\/jcpt.12200-BIB0070|jcpt12200-cit-0070","volume-title":"Cytovene (ganciclovir sodium for injection)","year":"2006"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12200","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12200","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12200\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T10:12:29Z","timestamp":1717323149000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,9]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12200","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9,9]]}}}